Discovery Landscape Awards (PhDs)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin sed orci ultrices, placerat magna sed, tincidunt magna.

  • Closing: 23rd December 2026
  • Starting: 4th February 2027
  • Duration:

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo. Quisque sit amet est et sapien ullamcorper pharetra. Vestibulum erat wisi, condimentum sed, commodo vitae, ornare sit amet, wisi. Aenean fermentum, elit eget tincidunt condimentum, eros ipsum rutrum orci, sagittis tempus lacus enim ac dui. Donec non enim in turpis pulvinar facilisis. Ut felis.

CTA image left

Supporting text below as a natural lead-in to the call to action

button label

Drawers

Award, Eligibility and Entry Requirements

Lorem ipsum dolor sit amet consectetur adipisicing elit. Blanditiis ducimus natus voluptas iure quos sunt sequi mollitia iusto nobis voluptatem, distinctio est necessitatibus nesciunt suscipit optio inventore ipsum laudantium tenetur.

Widening Participation

Strengthening our commitment to equality, diversity and inclusion (EDI)

In line with the NIHR's national strategy we aim to:

  • foster an inclusive environment
  • engage the talents and energy of diverse people in all areas of our work
  • improve the relevance and quality of our research

To do this we will widen access for greater diversity and inclusion of applicants across under-represented groups. This includes, but is not restricted to gender and sexuality, diverse racial and ethnic groups, people from different geographical regions of varied socio-economic backgrounds, people with disabilities or lived experience of mental health issues.

People with lived experience of neurodevelopmental and mental health conditions are actively encouraged to apply.

Training

Lorem ipsum dolor sit amet consectetur adipisicing elit. Beatae, officia ab magni illum corporis voluptates illo ea quod nam suscipit ipsa commodi consectetur sed aspernatur voluptas dolorum iste itaque laboriosam.

Application Process - Stages One to Three

Lorem ipsum dolor sit amet consectetur adipisicing elit. Beatae, officia ab magni illum corporis voluptates illo ea quod nam suscipit ipsa commodi consectetur sed aspernatur voluptas dolorum iste itaque laboriosam.

Projects

DT3-001 Developing a new online intervention to target transdiagnostic processes in anxiety and depression

  • 3 years
  • Dementias and Neurodegeneration

DT3-002 Developing a digital intervention to support food-related quality of life and disordered eating in people living with inflammatory bowel disease

  • 3 years
  • Genomics and Rare Diseases

DT3-003 Inclusive human-centred design of novel therapeutic targets in a digitally supported therapy for psychosis

  • 3 years
  • Dementias and Neurodegeneration

DT3-004 Improving access to an evidence-based digital therapeutic for treating depression and anxiety in long-term conditions (COMPASS) for Black Asian and Minority Ethnic (BAME) groups

  • 3 years
  • Genomics and Rare Diseases

IN3-001 Evaluating the impact of medication side effects and increasing their recognition in clinical practice

  • 3 years
  • Genomics and Rare Diseases

IN3-002 Multimodal machine learning in electronic health records for prognosis and diagnosis of rare neurological disorders

  • 3 years
  • Dementias and Neurodegeneration

PA3-001 Using ecological momentary assessment to innovate the biopsychosocial assessment and treatment of pain in people with Parkinson’s

  • 3 years
  • Metabolic and Endocrine Disorders

PA3-002 Understanding Pain Mechanisms of Central Sensitization in Humans Using functional MRI, Psychometric and Psychophysical Assessment

  • 3 years
  • Public Health and Prevention

TG3-001 Polygenic stratification of mental disorders to explore differential environmental exposures, clinical profiles, and treatment response

  • 3 years
  • Public Health and Prevention

PP3-001 atient and carer involvement in personalization and measuring treatment efficacy

  • 3 years
  • Metabolic and Endocrine Disorders

CO4-001 sing real-world evidence to emulate the cost-effectiveness of different treatment sequences of antipsychotic medication

  • 4 years
  • Genomics and Rare Diseases

CO4-002 ncovering GABAergic mechanisms in people at clinical high-risk for psychosis through pharmacological MRI

  • 4 years
  • Public Health and Prevention

CO4-003 Neural Markers of Prospective Negative Thought in Anxiety, A Computational and Pharmaco-Physiological Analysis

  • 4 years
  • Dementias and Neurodegeneration

CO4-004 Identification of modifiable risk factors for increased health care use in people with dementia and developing opportunities for intervention

  • 4 years
  • Genomics and Rare Diseases

CO4-005 An experimental medicine study of cannabidiol (CBD) and dronabinol as treatments for cannabis use disorder in teenagers who regularly use cannabis

  • 4 years
  • Public Health and Prevention

CO4-006 What works in supporting people with mental health problems into work: a data linkage study

  • 4 years
  • Genomics and Rare Diseases

CO4-007 A multi-centre, double-blind, parallel-group, randomized controlled study to compare the efficacy of real versus sham external Trigeminal Nerve Stimulation (eTNS) on symptoms in youth with Attention Deficit/Hyperactivity Disorder (ADHD) (ATTENS)

  • 4 years
  • Public Health and Prevention

CO4-008 Assessing a novel oculomotor biomarker of Attention Deficit/Hyperactivity Disorder (ADHD) and examining the efficacy of anti-saccade eye movement training as a novel intervention.

  • 4 years
  • Public Health and Prevention

CO4-009 Towards tailored treatment: Predicting real-world outcomes to first-line augmentation interventions for treatment-resistant depression

  • 4 years
  • Dementias and Neurodegeneration

CO4-010 Feasibility and acceptability of speech and mood data collection in daily life after traumatic brain injury (TBI) using digital technology

  • 4 years
  • Genomics and Rare Diseases

CO4-011 Enhancing psychosis prevention through dynamic refinement of a clinical prediction model using machine learning

  • 4 years
  • Genomics and Rare Diseases

CO4-012 The iADJUST study: Examining the trajectories of depressive and anxiety symptoms among incident dialysis patients and testing the feasibility of a tailored psychological intervention to improve mental health outcomes

  • 4 years
  • Genomics and Rare Diseases

CO4-013 Suicidal behaviour: An investigation of online temporal trends and electronic health records

  • 4 years
  • Genomics and Rare Diseases

CO4-014 Social media, mental health and self-harm behaviour in young people

  • 4 years
  • Genomics and Rare Diseases

CO4-015 Biomarkers for Autism and ADHD using EEG Data with Regularized Multivariate Statistical Methods.

  • 4 years
  • Dementias and Neurodegeneration

CO4-016 Understanding how anti-inflammatories help people with depression

  • 4 years
  • Dementias and Neurodegeneration

CO4-017 Shifting dynamic functional brain dynamics using pharmacological challenges in adults with and without autism spectrum disorder

  • 4 years
  • Public Health and Prevention

CO4-018 Cannabidiol for psychosis in Parkinson’s disease psychosis

  • 4 years
  • Public Health and Prevention

CO4-019 Experimental TESTing on Heroin and opioid OverDose: Environmental, Respiratory and Pharmacological Mechanisms (OD-TEST).

  • 4 years
  • Dementias and Neurodegeneration

CO4-020 Exploring the neurochemical and cognitive mechanisms underlying a novel EEG biomarker for autism.

  • 4 years
  • Public Health and Prevention

CO4-021 Biopsychosocial mechanisms underpinning the association between a singing intervention for mothers with postnatal depression and improvements in the mother-infant relationship

  • 4 years
  • Dementias and Neurodegeneration

CO4-022 Biomarker discovery using pharmaceutical challenge: shiftability studies to probe neural underpinnings.

  • 4 years
  • Genomics and Rare Diseases

CO4-023 Infant Predictors of Behavioural and Developmental Outcomes in Early-Onset Epilepsy: Integrating Neurocognition and Electronic Health Records

  • 4 years
  • Genomics and Rare Diseases

CO4-024 Ketamine and reward: understanding the effects on function and physiology in responders and non-responders

  • 4 years
  • Dementias and Neurodegeneration

CO4-025 Neuroimaging signatures of the antidepressant response to ketamine

  • 4 years
  • Dementias and Neurodegeneration

CO4-026 Dissecting the Epigenetic Basis of Eating Disorders in EDGI and Nanopore DNA Methylation Sequencing Data

  • 4 years
  • Genomics and Rare Diseases

CO4-027 Identifying Drug Repositioning Opportunities Through Leveraging the Core Neurogenetics of Major Depressive Disorder

  • 4 years
  • Genomics and Rare Diseases

CO4-028 Identifying social and behavioural intervention targets to reduce the impact of cardiovascular disease on mental health

  • 4 years
  • Genomics and Rare Diseases

CO4-029 Making life with psychosis easier: evaluation of a portable, capillary sampling device to reduce the burden of routine monitoring of full blood count in people taking clozapine.

  • 4 years
  • Genomics and Rare Diseases

CO4-030 Synaptic connectivity in Schizophrenia

  • 4 years
  • Dementias and Neurodegeneration

CO4-031 Identifying trajectories of psychiatric risk and resilience during development (THRIVE)

  • 4 years
  • Dementias and Neurodegeneration

CO4-032 The role of glutamatergic function in the neurobiology of treatment-resistant schizophrenia

  • 4 years
  • Dementias and Neurodegeneration

CO4-033 Using deep phenotyping informatics to map the prevalence, process and outcomes of people with neuropsychiatric disorders

  • 4 years
  • Dementias and Neurodegeneration

CO4-034 Developing novel diagnostic biomarkers for Functional Neurological Disorder

  • 4 years
  • Genomics and Rare Diseases

CO4-035 Machine learning approaches to high-dimensional mediation: explaining outcomes following psychological therapy for anxiety or depressive disorders

  • 4 years
  • Dementias and Neurodegeneration

CO4-036 Flexible machine learning models to capture the dynamics of patient outcomes at scale: learning from routinely- and remotely-collected health data

  • 4 years
  • Genomics and Rare Diseases

CO4-037 Cohort identification for mental health clinical trials: a knowledge graph approach

  • 4 years
  • Genomics and Rare Diseases

CO4-038 Developing an open-source speech analysis toolkit for clinical applications

  • 4 years
  • Genomics and Rare Diseases

CO4-039 How does trauma-focused psychological therapy for dual diagnosis psychosis and Post-Traumatic Stress Disorder patients affect the mind and brain?

  • 4 years
  • Public Health and Prevention

CO4-040 Virtual Reality Boosted Cognitive Remediation for People with Psychosis to Improve Recovery Outcomes

  • 4 years
  • Dementias and Neurodegeneration

CO4-041 Targeting Cognitive Inflexibility to Augment Anxiety Treatments for Autistic Youth: A precision psychiatry approach

  • 4 years
  • Genomics and Rare Diseases

CO4-042 Identifying a transdiagnostic biomarker of dissociative states in health and disease

  • 4 years
  • Dementias and Neurodegeneration

CO4-043 Developing neurophysiological and cognitive biomarkers for antipsychotic response in First Episode of Psychosis

  • 4 years
  • Dementias and Neurodegeneration

CO4-044 Using virtual reality to investigate sense of body ownership and agency in patients with functional neurological disorder and patients with schizophrenia.

  • 4 years
  • Public Health and Prevention

CO4-045 Exploring Multi-omics based Machine Learning approaches for the prediction of disease progression and patient stratification in clinical trials of neuropsychiatric disorders

  • 4 years
  • Public Health and Prevention

CO4-046 Selectively shifting the GABA system in autism; a promising target for interventions?

  • 4 years
  • Public Health and Prevention

CO4-047 Novel digital tools and therapies to improve the mental health of autistic people.

  • 4 years
  • Genomics and Rare Diseases

CO4-048 Transcranial Direct Current Stimulation and Virtual Reality Exposure Therapy for Anorexia Nervosa

  • 4 years
  • Public Health and Prevention